Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

KJ Mason, AD Burden, MK Rutter… - Journal of the …, 2020 - Wiley Online Library
Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVE s; acute …
被引用次数：37 相关文章

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of …

W Rungapiromnan, KJ Mason… - … and Drug Safety, 2019 - keele-repository.worktribe.com
Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVE s; acute …

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

W Rungapiromnan, KJ Mason, M Lunt… - Journal of the …, 2020 - search.ebscohost.com
Background: The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives: To compare the risk of major cardiovascular events (CVEs; acute …

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

W Rungapiromnan, KJ Mason, M Lunt… - Journal of the …, 2020 - eprints.gla.ac.uk
Background: The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives: To compare the risk of major cardiovascular events (CVEs; acute …

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

W Rungapiromnan, KJ Mason… - Journal of the …, 2020 - pubmed.ncbi.nlm.nih.gov
Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVEs; acute …

Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study

W Rungapiromnan, KJ Mason… - Journal of the …, 2020 - research.manchester.ac.uk
OBJECTIVES To compare the risk of major cardiovascular events (CVEs; acute coronary
syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque …

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.

W Rungapiromnan, KJ Mason, M Lunt… - Journal of the …, 2019 - europepmc.org
Objectives To compare the risk of major cardiovascular events (CVEs; acute coronary
syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque …
[PDF] scienceopen.com

[PDF][PDF] Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

W Rungapiromnan, KJ Mason, M Lunt, K McElhone… - 2019 - scienceopen.com
Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVEs; acute …
[PDF] core.ac.uk

[PDF][PDF] Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

W Rungapiromnan, KJ Mason, M Lunt, K McElhone… - 2019 - core.ac.uk
Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVEs; acute …
[HTML] nih.gov

[HTML][HTML] Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

W Rungapiromnan, KJ Mason, M Lunt… - Journal of the …, 2020 - ncbi.nlm.nih.gov
Objectives To compare the risk of major cardiovascular events (CVE s; acute coronary
syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque …